MedTrace Logo

PET Study of Repeated ASN51 in Healthy Volunteers

NCT05725005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-05-08

Study results available
· View outcomes & findings →

Summary

This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs), after repeated doses of ASN51 in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

ASN51

Oral capsule

Sponsors & Collaborators

  • Hammersmith Medicines Research

    collaborator OTHER

  • Invicro

    collaborator OTHER

  • Asceneuron S.A.

    lead INDUSTRY

Principal Investigators

  • Adeep Puri, MD · Hammersmith Medicines Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
22 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-26
Primary Completion
2023-04-04
Completion
2023-06-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725005 on ClinicalTrials.gov